M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
Status:
Terminated
Trial end date:
2016-10-24
Target enrollment:
Participant gender:
Summary
People with primary metastatic pancreatic cancer will be treated with nab-paclitaxel and
gemcitabine in combination with an investigational agent called necuparanib (M402). It is
made from heparin, which is a well known blood thinner. Blood thinners have been shown in
prior animal and human studies to have anti-cancer effects. Necuparanib has been
re-engineered from heparin to have much lower blood thinning activity while keeping the
anti-tumor activity. The investigators are testing whether necuparanib administered in
combination with nab-paclitaxel and gemcitabine may be more effective than nab-paclitaxel and
gemcitabine.